Research Summary: For patients with bacillus Calmette-Guérin (BCG)–naïve, high-risk non-muscle invasive bladder cancer (NMIBC), the
Research Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors
Research Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that
Research Summary: Unresectable, stage III non-small cell lung cancer (NSCLC) is treated with concurrent chemoradiotherapy
Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung
Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that
Learn how capivasertib plus fulvestrant works in advanced breast cancer, including its effectiveness, safety, and why this dosing approach may help improve treatment outcomes.
Learn how acalabrutinib compares to other CLL treatments, with insights on cardiac safety, atrial fibrillation risk, and what recent trials reveal about treatment options.
Research Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is
Research Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth
Research Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor
Research Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell
Research Summary: The EMBER-3 trial1 was a Phase III, open-label study that evaluated imlunestrant, a
Research Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting,
Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine
Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor
Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T)
Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy
This study examines how the FOXO3–FOXM1 regulatory axis influences sensitivity to AKT inhibition in PIK3CA- and PIK3CA/PTEN-altered estrogen receptor–positive breast cancer.
©2026 Oncology Matrix. All Rights Reserved.
